Hikma Warns Of Renewed Pricing Pressure On US Generics
Provides Update On Key Products And Announces $300m Share Buyback
Hikma has warned of renewed pressure on generics in the US after a “gradual worsening of the pricing environment” in 2021. However, the company still managed to achieve growth of a tenth in its generics segment last year, on the back of key launches.